• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于患者风险因素和接种疫苗数量的新冠肺炎严重程度预测计算器。

A Calculator for COVID-19 Severity Prediction Based on Patient Risk Factors and Number of Vaccines Received.

作者信息

Israel Ariel, Schäffer Alejandro A, Merzon Eugene, Green Ilan, Magen Eli, Golan-Cohen Avivit, Vinker Shlomo, Ruppin Eytan

机构信息

Leumit Health Services, Tel-Aviv 6473817, Israel.

Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

出版信息

Microorganisms. 2022 Jun 16;10(6):1238. doi: 10.3390/microorganisms10061238.

DOI:10.3390/microorganisms10061238
PMID:35744754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9229599/
Abstract

Vaccines have allowed for a significant decrease in COVID-19 risk, and new antiviral medications can prevent disease progression if given early in the course of the disease. The rapid and accurate estimation of the risk of severe disease in new patients is needed to prioritize the treatment of high-risk patients and maximize lives saved. We used electronic health records from 101,039 individuals infected with SARS-CoV-2, since the beginning of the pandemic and until 30 November 2021, in a national healthcare organization in Israel to build logistic models estimating the probability of subsequent hospitalization and death of newly infected patients based on a few major risk factors (age, sex, body mass index, hemoglobin A1C, kidney function, and the presence of hypertension, pulmonary disease, and malignancy) and the number of BNT162b2 mRNA vaccine doses received. The model's performance was assessed by 10-fold cross-validation: the area under the curve was 0.889 for predicting hospitalization and 0.967 for predicting mortality. A total of 50%, 80%, and 90% of death events could be predicted with respective specificities of 98.6%, 95.2%, and 91.2%. These models enable the rapid identification of individuals at high risk for hospitalization and death when infected, and they can be used to prioritize patients to receive scarce medications or booster vaccination. The calculator is available online.

摘要

疫苗已使新冠病毒感染风险显著降低,新型抗病毒药物若在疾病早期使用,可预防疾病进展。为了优先治疗高危患者并最大程度挽救生命,需要快速准确地评估新患者的重症风险。自疫情开始至2021年11月30日,我们利用以色列一家全国性医疗保健机构中101039名感染新冠病毒个体的电子健康记录,构建逻辑模型,根据一些主要风险因素(年龄、性别、体重指数、糖化血红蛋白、肾功能,以及是否存在高血压、肺部疾病和恶性肿瘤)和接种BNT162b2 mRNA疫苗的剂量,估算新感染患者随后住院和死亡的概率。通过10倍交叉验证评估模型性能:预测住院的曲线下面积为0.889,预测死亡率的曲线下面积为0.967。分别以98.6%、95.2%和91.2%的特异性,可预测总共50%、80%和90%的死亡事件。这些模型能够快速识别感染时具有高住院和死亡风险的个体,可用于优先安排患者接受稀缺药物治疗或加强疫苗接种。该计算器可在线获取。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8825/9229599/9402fcc6e541/microorganisms-10-01238-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8825/9229599/f9bcb2371396/microorganisms-10-01238-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8825/9229599/9402fcc6e541/microorganisms-10-01238-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8825/9229599/f9bcb2371396/microorganisms-10-01238-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8825/9229599/9402fcc6e541/microorganisms-10-01238-g002.jpg

相似文献

1
A Calculator for COVID-19 Severity Prediction Based on Patient Risk Factors and Number of Vaccines Received.基于患者风险因素和接种疫苗数量的新冠肺炎严重程度预测计算器。
Microorganisms. 2022 Jun 16;10(6):1238. doi: 10.3390/microorganisms10061238.
2
Predicting COVID-19 severity using major risk factors and received vaccines.利用主要风险因素和接种疫苗情况预测新冠病毒疾病的严重程度。
medRxiv. 2022 Jan 3:2021.12.31.21268575. doi: 10.1101/2021.12.31.21268575.
3
Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.2021 年 8 月至 10 月,BNT162b2 疫苗第三剂接种与长期护理机构居民 SARS-CoV-2 感染、COVID-19 相关住院和死亡的相关性。
JAMA Netw Open. 2022 Jul 1;5(7):e2219940. doi: 10.1001/jamanetworkopen.2022.19940.
4
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
5
Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.川崎病病史患者对 COVID-19 感染和信使 RNA 疫苗接种的耐受性。
JAMA Netw Open. 2022 Aug 1;5(8):e2226236. doi: 10.1001/jamanetworkopen.2022.26236.
6
Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.意大利 12 至 39 岁人群接种 COVID-19 mRNA 疫苗后的心肌炎和心包炎上市后主动监测:多数据库、自身对照病例系列研究。
PLoS Med. 2022 Jul 28;19(7):e1004056. doi: 10.1371/journal.pmed.1004056. eCollection 2022 Jul.
7
Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.3 个月时用灭活 COVID-19 疫苗进行异源和同源加强与 6 个月时用 BNT162b2 进行同源加强的比较。
JAMA Netw Open. 2022 Aug 1;5(8):e2226046. doi: 10.1001/jamanetworkopen.2022.26046.
8
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.同源和异源加强针对于灭活 SARS-CoV-2 疫苗的有效性:一项大规模前瞻性队列研究。
Lancet Glob Health. 2022 Jun;10(6):e798-e806. doi: 10.1016/S2214-109X(22)00112-7. Epub 2022 Apr 23.
9
The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.自然获得性免疫人群和随后接种 1 剂 BNT162b2 疫苗人群中 SARS-CoV-2 再感染发生率:一项回顾性队列研究。
Ann Intern Med. 2022 May;175(5):674-681. doi: 10.7326/M21-4130. Epub 2022 Feb 15.
10
Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.在未感染和既往感染个体中,接受 BNT162b2 疫苗第一、第二和第三剂后,针对 SARS-CoV-2 的特异性抗体反应的差异:一项在医护人员中进行的为期 1 年的观察性研究。
Front Immunol. 2022 May 27;13:876533. doi: 10.3389/fimmu.2022.876533. eCollection 2022.

引用本文的文献

1
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2.专家共识:影响 COVID-19 预后不良的主要危险因素及其对靶向 SARS-CoV-2 措施的影响。
Viruses. 2023 Jun 27;15(7):1449. doi: 10.3390/v15071449.
2
Risk Stratification Model for Severe COVID-19 Disease: A Retrospective Cohort Study.重症新型冠状病毒肺炎疾病风险分层模型:一项回顾性队列研究。
Biomedicines. 2023 Mar 2;11(3):767. doi: 10.3390/biomedicines11030767.
3
First cases of Omicron in France are exhibiting mild symptoms, November 2021-January 2022.

本文引用的文献

1
The First 110,593 COVID-19 Patients Hospitalised in Lombardy: A Regionwide Analysis of Case Characteristics, Risk Factors and Clinical Outcomes.伦巴第地区 110593 例新冠肺炎住院患者:对病例特征、风险因素和临床结局的全地区分析。
Int J Public Health. 2022 May 11;67:1604427. doi: 10.3389/ijph.2022.1604427. eCollection 2022.
2
Fair Allocation of Scarce Therapies for Coronavirus Disease 2019 (COVID-19).公平分配 2019 年冠状病毒病(COVID-19)稀缺疗法。
Clin Infect Dis. 2022 Aug 24;75(1):e529-e533. doi: 10.1093/cid/ciab1039.
3
Booster Doses and Prioritizing Lives Saved.
法国首批奥密克戎感染病例症状轻微,时间为 2021 年 11 月至 2022 年 1 月。
Infect Dis Now. 2022 May;52(3):160-164. doi: 10.1016/j.idnow.2022.02.003. Epub 2022 Feb 12.
加强剂量与拯救生命的优先级
N Engl J Med. 2021 Dec 23;385(26):2476-2477. doi: 10.1056/NEJMe2117592. Epub 2021 Dec 8.
4
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.奥密克戎新冠病毒变体:新冠疫情的新篇章。
Lancet. 2021 Dec 11;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6. Epub 2021 Dec 3.
5
How bad is Omicron? What scientists know so far.奥密克戎毒株有多严重?科学家目前所了解的情况。
Nature. 2021 Dec;600(7888):197-199. doi: 10.1038/d41586-021-03614-z.
6
Covid-19: FDA expert panel recommends authorising molnupiravir but also voices concerns.新冠疫情:美国食品药品监督管理局专家小组建议批准莫努匹拉韦,但也表达了担忧。
BMJ. 2021 Dec 2;375:n2984. doi: 10.1136/bmj.n2984.
7
A Predictive Model for Severe COVID-19 in the Medicare Population: A Tool for Prioritizing Primary and Booster COVID-19 Vaccination.医疗保险人群中重症 COVID-19 的预测模型:一种用于确定 COVID-19 初种和加强疫苗接种优先级的工具。
Biology (Basel). 2021 Nov 15;10(11):1185. doi: 10.3390/biology10111185.
8
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study.辉瑞疫苗(BNT162b2)接种后时间与 SARS-CoV-2 感染风险:阴性检测设计研究。
BMJ. 2021 Nov 24;375:e067873. doi: 10.1136/bmj-2021-067873.
9
The Prediction Model of Risk Factors for COVID-19 Developing into Severe Illness Based on 1046 Patients with COVID-19.基于1046例新型冠状病毒肺炎患者的新型冠状病毒肺炎重症化危险因素预测模型
Emerg Med Int. 2021 Nov 18;2021:7711056. doi: 10.1155/2021/7711056. eCollection 2021.
10
Factors associated with admission to the intensive care unit and mortality in patients with COVID-19, Colombia.与 COVID-19 患者入住重症监护病房和死亡相关的因素,哥伦比亚。
PLoS One. 2021 Nov 19;16(11):e0260169. doi: 10.1371/journal.pone.0260169. eCollection 2021.